IRWD — Stock Film
STOCK FILMSCENE 1/11IRWD · $3.86
Stock Expert AI presents
IRWD
Ironwood Pharmaceuticals, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Ironwood Pharmaceuticals, Inc. A quick introduction.

On the stock market since 2010, it operates in the world of health and science. It has 100 employees. Now — the numbers.

on the stock market since 2010
100 employees
$635.4M market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $8 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 8%

This is an established company with proven profits.

WHERE DOES THE MONEY COME FROM?
99%Collaborative Arrangements
Collaborative Arrangements 99%Collaborative arrangement, collaboration and license agreements 1%Royalty <1%Collaborative arrangement, other agreements <1%
99% of all revenue comes from a single line: Collaborative Arrangements.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

THE SALES TREND
Sales have been shrinking.

An average decline of 8% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.

$413.8M
2021
$410.6M
2022
$442.7M
2023
$351.4M
2024
$296.2M
2025
INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
96
very strong

Profit power and business quality lead the class.

FINANCIAL STRENGTH
92
very strong

A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.

VALUATION
77
strong

Clearly above the class average — a step short of the very top.

GROWTH
36
weak

Clearly below the class average.

PRICE MOMENTUM
77
strong

Clearly above the class average — a step short of the very top.

WORTH WATCHING

Growth: Sales growth trails the sector average.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Fat profit per sale, but shrinking10/10
Heavy investment in the future10/10
Few are betting against it10/10
WEAK SPOTS
Growth has stalled2/10
WORTH WATCHING

Revenue Growth: Sales are growing slowly.

THE FIVE-YEAR JOURNEY
A big climb, then a hard fall.

An investor who bought at the very peak is down 75% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/1
Executives are buying their own stock

Over the last 12 months, company executives reported 19 buys and 17 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/3
Sales are shrinking

Over the last 3 years, sales fell about 10% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.

2
THE RISKS · 2/3
Growth trails the sector

The growth engine is running at low revs right now. Report-card grade: 36/100.

3
THE RISKS · 3/3
Growth has stalled

The sales tempo runs behind the sector. Council score: 2/10.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, IRWD sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: IRWD is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 24, 2026 · stockexpertai.com · Stock Film